This site is intended for Healthcare Professionals only.

BioNTech signs deal with UK for personalised cancer therapies

Date:

Share post:

German biotechnology company BioNTech has signed a deal with the Department of Health and Social Care to enroll up to 10,000 patients in clinical trials by the end of 2030 for personalized cancer therapies, the German drug maker said.

The multi-year collaboration is focused on cancer immunotherapies based on mRNA or other drug classes, infectious disease vaccines, and investments into expanding the company’s footprint in the UK, BioNTech said in a statement on Thursday (January 5).

Under the agreement, the parties plan to utilize UK’s clinical trial network, genomics and health data assets, aiming to enroll the first cancer patient in the second half of 2023, the company said.

BioNTech, which partnered with U.S. pharmaceutical group Pfizer to develop a COVID vaccine, said it would open a research and development hub with more than 70 scientists in Cambridge.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

RPS releases general election manifesto: Key asks revealed

It urges the next government to review prescription charges in England and strengthen the UK’s medicines supply...

CCA urges urgent action on shortage of designated prescribing practitioners

It has repeatedly warned NHS England of the likely consequences arising from the lack of designated prescribing practitioners  The...

First pharmacist to lead training initiatives for critical care professionals: Reena Mehta

Spearheading the educational efforts and training initiatives for the Intensive Care Society, Reena Mehta ,the first pharmacist, to...

#Fight4Pharmacies: IPA warns ‘there simply won’t be enough community pharmacies left to deliver PFS”

'95 per cent community pharmacies rely on the NHS to sustain,' according to Fight4Pharmacies petition "If the Government does...